multicenter cohort
Recently Published Documents


TOTAL DOCUMENTS

1721
(FIVE YEARS 809)

H-INDEX

64
(FIVE YEARS 13)

2022 ◽  
Vol 11 (2) ◽  
pp. 413
Author(s):  
César Fernández-de-las-Peñas ◽  
José D. Martín-Guerrero ◽  
Óscar J. Pellicer-Valero ◽  
Esperanza Navarro-Pardo ◽  
Víctor Gómez-Mayordomo ◽  
...  

This multicenter cohort study investigated the differences between coronavirus disease 2019 (COVID-19) related symptoms and post-COVID symptoms between male and female COVID-19 survivors. Clinical and hospitalization data were collected from hospital medical records in a sample of individuals recovered from COVID-19 at five public hospitals in Spain. A predefined list of post-COVID symptoms was systematically assessed, but patients were free to report any symptom. Anxiety/depressive levels and sleep quality were also assessed. Adjusted multivariate logistic regressions were used to identify the association of sex with post-COVID related-symptoms. A total of 1969 individuals (age: 61, SD: 16 years, 46.4% women) were assessed 8.4 months after discharge. No overall significant sex differences in COVID-19 onset symptoms at hospital admission were found. Post-COVID symptoms were present in up to 60% of hospitalized COVID-19 survivors eight months after the infection. The number of post-COVID symptoms was 2.25 for females and 1.5 for males. After adjusting by all variables, female sex was associated with ≥3 post-COVID symptoms (adj OR 2.54, 95%CI 1.671–3.865, p < 0.001), the presence of post-COVID fatigue (adj OR 1.514, 95%CI 1.040–2.205), dyspnea (rest: adj OR 1.428, 95%CI 1.081–1.886, exertion: adj OR 1.409, 95%CI 1.109–1.791), pain (adj OR 1.349, 95%CI 1.059–1.720), hair loss (adj OR 4.529, 95%CI 2.784–7.368), ocular problems (adj OR 1.981, 95%CI 1.185–3.312), depressive levels (adj OR 1.606, 95%CI 1.002–2.572) and worse sleep quality (adj OR 1.634, 95%CI 1.097–2.434). Female sex was a risk factor for the development of some long-term post-COVID symptoms including mood disorders. Healthcare systems should consider sex differences in the management of long haulers.


Critical Care ◽  
2022 ◽  
Vol 26 (1) ◽  
Author(s):  
Yunjoo Im ◽  
Danbee Kang ◽  
Ryoung-Eun Ko ◽  
Yeon Joo Lee ◽  
Sung Yoon Lim ◽  
...  

Abstract Background Timely administration of antibiotics is one of the most important interventions in reducing mortality in sepsis. However, administering antibiotics within a strict time threshold in all patients suspected with sepsis will require huge amount of effort and resources and may increase the risk of unintentional exposure to broad-spectrum antibiotics in patients without infection with its consequences. Thus, controversy still exists on whether clinicians should target different time-to-antibiotics thresholds for patients with sepsis versus septic shock. Methods This study analyzed prospectively collected data from an ongoing multicenter cohort of patients with sepsis identified in the emergency department. Adjusted odds ratios (ORs) were compared for in-hospital mortality of patients who had received antibiotics within 1 h to that of those who did not. Spline regression models were used to assess the association of time-to-antibiotics as continuous variables and increasing risk of in-hospital mortality. The differences in the association between time-to-antibiotics and in-hospital mortality were assessed according to the presence of septic shock. Results Overall, 3035 patients were included in the analysis. Among them, 601 (19.8%) presented with septic shock, and 774 (25.5%) died. The adjusted OR for in-hospital mortality of patients whose time-to-antibiotics was within 1 h was 0.78 (95% confidence interval [CI] 0.61–0.99; p = 0.046). The adjusted OR for in-hospital mortality was 0.66 (95% CI 0.44–0.99; p = 0.049) and statistically significant in patients with septic shock, whereas it was 0.85 (95% CI 0.64–1.15; p = 0.300) in patients with sepsis but without shock. Among patients who received antibiotics within 3 h, those with septic shock showed 35% (p = 0.042) increased risk of mortality for every 1-h delay in antibiotics, but no such trend was observed in patients without shock. Conclusion Timely administration of antibiotics improved outcomes in patients with septic shock; however, the association between early antibiotic administration and outcome was not as clear in patients with sepsis without shock.


Author(s):  
Takaaki Kishino ◽  
Naoyoshi Nagata ◽  
Katsumasa Kobayashi ◽  
Atsushi Yamauchi ◽  
Atsuo Yamada ◽  
...  

Allergy ◽  
2022 ◽  
Author(s):  
Makiko Nanishi ◽  
Michimasa Fujiogi ◽  
Robert J. Freishtat ◽  
Claire E. Hoptay ◽  
Cindy S. Bauer ◽  
...  

2022 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Guosong Wu ◽  
Andrea Soo ◽  
Paul Ronksley ◽  
Jayna Holroyd-Leduc ◽  
Sean M. Bagshaw ◽  
...  

2022 ◽  
Vol 226 (1) ◽  
pp. S57-S58
Author(s):  
Lorraine Dugoff ◽  
Nathanael C. Koelper ◽  
Stephen T. Chasen ◽  
Melissa L. Russo ◽  
Ashley S. Roman ◽  
...  

2021 ◽  
Author(s):  
Nozomu Kobayashi ◽  
Yoji Takeuchi ◽  
Ken Ohata ◽  
Masahiro Igarashi ◽  
Masayoshi Yamada ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
pp. 81
Author(s):  
Fabian Queissert ◽  
Keith Rourke ◽  
Sandra Schönburg ◽  
Alessandro Giammò ◽  
Andreas Gonsior ◽  
...  

(1) Background: This study examined outcomes of second-line ATOMS implantation after failure of the fixed male sling (FMS) AdVance/AdVance XP. (2) Methods: A retrospective multicenter cohort analysis was carried out in men implanted with an ATOMS between 2011 and 2020 after failure of an AdVance/AdVance XP. Success was assessed on the basis of objective (dryness, 0–1 pad/24 h or >20 g/24 h pad test) and subjective results (PGI-I). We performed the Wilcoxon rank sum test, Fisher’s exact test, logistic regression, and multivariate analysis. (3) Results: The study included 88 patients from 9 centers with a mean age of 71.3 years. No Clavien–Dindo > II complications occurred within the first 3 months after ATOMS implantation. A total of 10 cases (9%) required revision in the ensuing clinical course. After a mean follow-up of 42.5 months, 76.1% achieved social continence, and 56.8% used no pads at all. Mean urine leakage/24 h dropped from 422 g (3.9 pads) to 38 g (0.69 pads) and the mean ICIQ-SF decreased from 16.25 to 5.3 (p < 0.0001). PROMs (patient-reported outcome measures) showed improvement in 98.9% of cases, and 63.6% gave a “very much better” PGI-I rating. Multivariate analysis identified a lower probability of achieving maximum satisfaction for the following factors: the AdVance XP as first-line therapy (OR 0.35), a lower ICIQ-SF question 1 (OR 0.26), status post-irradiation (OR 0.14), and more severe pain prior to ATOMS implantation (OR 0.51). (4) Conclusions: Implantation of an ATOMS is an effective and safe second-line treatment option for recurrent urinary incontinence after implantation of an AdVance/AdVance XP sling. High patient satisfaction was demonstrated in a long-term follow-up.


Sign in / Sign up

Export Citation Format

Share Document